Karyopharm Therapeutics (KPTI) Inventory (2019 - 2025)

Karyopharm Therapeutics has reported Inventory for 7 years, with the latest figure at $4.0 million in Q4 2025.

• For the quarter ending Q4 2025, Inventory fell 14.79% year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2025 stood at $4.0 million (down 14.79% YoY), and the FY2025 full-year result was $4.0 million, down 14.79% from the prior year.
• Inventory for Q4 2025 stood at $4.0 million, up from $4.0 million in the prior quarter.
• The five-year high for Inventory was $5.0 million in Q2 2025, with the low at $2.8 million in Q1 2024.
• Historically, Inventory has averaged $3.9 million across 5 years, with a median of $3.9 million in 2021.
• Annual changes were most pronounced in 2021 — Inventory surged 221.03% — and 2023, when it declined 27.96%.
• Karyopharm Therapeutics' Inventory stood at $4.1 million in 2021, then grew by 2.87% to $4.2 million in 2022, then slipped by 27.96% to $3.0 million in 2023, then surged by 55.73% to $4.7 million in 2024, then retreated by 14.79% to $4.0 million in 2025.
• The last three Inventory figures came in at $4.0 million (Q4 2025), $4.0 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.